Actionable news
All posts from Actionable news
Actionable news in NLNK: NewLink Genetics Corporation,

Shares Of NewLink Genetics Tumble 35% AH After Failed Phase 3 Trial

In after-hours trade on Monday shares of NewLink Genetics (NLNK) tumbled by 35% after the company announced that it had failed a phase 3 trial in patients with pancreatic cancer. The phase 3 trial, known as the IMPRESS phase 3 study, recruited a total of 722 patients with resected pancreatic cancer. The phase 3 trial failed to meet the primary endpoint, and NewLink's vaccine known as algenpantucel-L did not improve clinical outcome compared to control.

The primary...